Related references
Note: Only part of the references are listed.Regional lymphatic immunity in melanoma
Travis E. Grotz et al.
MELANOMA RESEARCH (2012)
Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine
Matthew S. Block et al.
MELANOMA RESEARCH (2011)
Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysis
Simone Mocellin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support
Paul A. Harris et al.
JOURNAL OF BIOMEDICAL INFORMATICS (2009)
Recombinant Human Granulocyte-macrophage Colony-stimulating Factor (GM-CSF, Sargramostim) Administered for 3 Years as Adjuvant Therapy of Stages II(T4), III, and IV Melanoma
Lynn E. Spitler et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Sequential administration of GM-CSF (Sargramostim®) and IL-2 ± autologous vaccine as adjuvant therapy in cutaneous melanoma:: An interim report of a phase II clinical trial
E. George Elias et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2008)
Share Paper
